The 22 references in paper И. Явелов С. (2016) “АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА: ЧТО МЫ ЗНАЕМ О ВОЗМОЖНОСТЯХ ИНДИВИДУАЛИЗАЦИИ” / spz:neicon:aterotromboz:y:2016:i:2:p:46-53

1
Jernberg T, Hjelm H, Hasvold P et al. Continued high CVD risk in myocardial infarction survivors: comparison of risk first and second year after MIresults from a Swedish nationwide study. Eur Heart J, 2014, 35(suppl. 1): 363.
(check this in PDF content)
2
Rapsomaniki E, Stogiannis D, Emmas C et al, on behalf of PEGASUS-TIMI-54. Health outcomes in patients with stable coronary artery disease following myocardial infarction; construction of a PEGASUS-TIMI-54 like population in UK linked electronic health records. Eur Heart J, 2014,
(check this in PDF content)
3
suppl. 1): 363. 3. Fox KAA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study). Eur Heart J,2010, 31: 27552764.
(check this in PDF content)
4
Stone GW, Maehara A, Lansky AJ et al, PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med, 2011, 364: 226-235.
(check this in PDF content)
5
Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J,2016, 37: 267-315.
(check this in PDF content)
6
2014 AHA/ACC Guidelines for the Management of Patients With Non–ST-Elevation Acute Coronary Syndrome: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 130: e344-e426.
(check this in PDF content)
7
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012, 33: 2569-2619.
(check this in PDF content)
8
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC, 2013, 61: 485-510.
(check this in PDF content)
9
Bonaca MP, Bhatt DL, Cohen M et al, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med, 2015, 372: 1791-1800.
(check this in PDF content)
10
Kereiakes DJ, Yeh RW, Massaro JM et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. JACC, 2016. http:// dx.doi.org/10.1016/j.jacc.2016.03.485.
(check this in PDF content)
11
Bates ER, Bittl JA, Brindis RG et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–STElevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Eva
(check this in PDF content)
12
Wallentin L, Becker RC, Budaj A et al, for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med,2009, 361: 1045-1057.
(check this in PDF content)
13
Mega JL, Braunwald E, Wiviott SD et al, ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 366: 9-19. всех этих неясностей при необходимости длительного применения высоких (лечебных) доз антикоагулянтов в первый год после ОКС разумно отдавать предпочтение Варфарину, прибегая к использованию пероральных антикоагулянтов прямого действия только в случаях, когда наладить надлежащее применение антагониста витамина К не представляется возможным.
(check this in PDF content)
14
2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014, 35: 2541-2619.
(check this in PDF content)
15
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J, 2016. doi:10.1093/eurheartj/ehw210.
(check this in PDF content)
16
Явелов И.С. Применение пероральных антикоагулянтов во вторичной профилактике острого коронарного синдрома: что известно к середине 2013 года. Трудный пациент, 2013, 11(7): 22-31.
(check this in PDF content)
17
Dewilde WJM, Oirbans T, Verheugt FWA et al, for the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013, 381: 1107-1115.
(check this in PDF content)
18
Lamberts M, Gislason GH, Olesen JB et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. JACC, 2013, 62: 981-989.
(check this in PDF content)
19
Sarafoff N, Martischnig A, Wealer J et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. JACC, 2013, 61: 2060-2066.
(check this in PDF content)
20
Lip GYH, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J,2014, http://dx.doi.org/10.1093/eurheartj/ehu298.
(check this in PDF content)
21
Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace,2015, 17: 1467-1507.
(check this in PDF content)
22
Dans AL, Connolly SJ, Wallentin L et al. Evaluation of Long-Term Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Anticoagulation Therapy (RE-LY) Trial. Circulation, 2013, 127: 634-640.
(check this in PDF content)